Analysis on Impact of COVID-19-Global Chloroquine market 2020-2024 | Evolving Opportunities with Abcam Plc and ADVANZ PHARMA Corp. | Technavio

LONDON–()–The global chloroquine market is expected to grow by USD 86.12 million as per Technavio. This marks a significant market slowdown compared to the previous year’s growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, healthy growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 3%.

Request challenges and opportunities that influence COVID-19 pandemic – Request free sample report of chloroquine market

COVID-19 cases in the US are increasing at a significant rate. European countries such as Italy, Germany, France, Spain, and the UK are also witnessing a rapid rise in the number of people infected with the virus. Many governments across the globe are working closely with pharmaceutical companies and research laboratories to identify potential treatment for coronavirus. For instance, on March 24, 2020, Europe began the clinical trials for various drugs, including chloroquine, to treat COVID-19 infected patients. With the rising number of COVID-19 cases, the market will witness a surge in the demand for chloroquine over the forecast period.

Read the 120-page report with TOC on “Chloroquine Market Analysis Report by Application (Malaria, Rheumatoid arthritis, and Others), Geography (North America, Europe, and Asia and ROW), and the Segment Forecasts, 2020-2024”.

https://www.technavio.com/report/global-chloroquine-market-2020-2024-industry-analysis

The market is driven by multiple indications of chloroquine. In addition, the increasing demand and production of chloroquine by key vendors is anticipated to boost the growth of the chloroquine market.

The growing prevalence of malaria and rheumatic diseases across the world has significantly increased the demand for chloroquine. For instance, in 2018, there were nearly 228 million cases of malaria across the world. Similarly, during 2013-2015, nearly 54.4 million adults in the US were struggling with arthritis, gout, lupus, and fibromyalgia. Moreover, in January 2020, chloroquine was identified as a potential drug candidate for the treatment of coronavirus. This is expected to further boost the growth of the global chloroquine market during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Chloroquine Companies:

Abcam Plc

Abcam Plc operates its business through the sales of antibodies and related products segment. The company offers Chloroquine diphosphate. It is an antimalarial agent with 98% purity that inhibits tumour cell growth and metastasis and induces apoptosis in vitro.

ADVANZ PHARMA Corp.

ADVANZ PHARMA Corp. operates its business through segments such as ADVANZ PHARMA International and ADVANZ PHARMA North America. The company offers Plaqueni, which is an antimalarial drug used for the treatment of lupus and rheumatoid arthritis.

Bayer AG

Bayer AG operates its business through segments such as Pharmaceuticals, Crop science, and Consumer health. The company offers Resochin Tablets. These tablets are effective against all four malaria parasites that infect humans, except for chloroquine-resistant species and Chronic polyarthritis (rheumatoid arthritis) including juvenile chronic arthritis.

Cadila Healthcare Ltd.

Cadila Healthcare Ltd. operates its business through the Pharmaceuticals segment. The company offers Hydroxychloroquine Sulfate Tablets. It also offers capsule-shaped; white to off-white; ZC38, antimalarial drug under the brand name, Plaquenil Tablets.

Ipca Laboratories Ltd.

Ipca Laboratories Ltd. operates its business through the Pharmaceuticals segment. The company offers antimalarial drugs in both syrup and tablet form in different compositions 40 mg, 250 mg, and 500 mg among others.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Chloroquine Market Application Outlook (Revenue, USD Million, 2020-2024)

  • Malaria
  • Rheumatoid arthritis
  • Others

Chloroquine Market Geography Outlook (Revenue, USD Million, 2020-2024)

  • North America
  • Europe
  • Asia
  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Anti-malarial Medicines Market – Global anti-malarial medicines market by product (artemisinin compounds, quinolines, and related compounds, and other compounds) and geographic landscape (APAC, Europe, MEA, North America, and South America).

Global Parasitic Diseases Therapeutics Market – Global parasitic diseases therapeutics market by type (antiprotozoal therapeutics, anthelminthic therapeutics, and scabicides and pediculicides therapeutics) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Source

About the Author: Biotech Today

You might like